FDC Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Net profit of FDC rose 167.39% to Rs 103.40 crore in the quarter ended March 2026 as against Rs 38.67 crore during the previous quarter ended March 2025. Sales rose 18.89% to Rs 584.79 crore in the quarter ended March 2026 as against Rs 491.89 crore during the previous quarter ended March 2025.

For the full year,net profit rose 5.48% to Rs 281.42 crore in the year ended March 2026 as against Rs 266.79 crore during the previous year ended March 2025. Sales rose 2.98% to Rs 2170.93 crore in the year ended March 2026 as against Rs 2108.12 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

Net profit of FDC rose 122.04% to Rs 107.07 crore in the quarter ended March 2026 as against Rs 48.22 crore during the previous quarter ended March 2025. Sales rose 17.09% to Rs 564.36 crore in the quarter ended March 2026 as against Rs 482.00 crore during the previous quarter ended March 2025.

For the full year,net profit rose 4.49% to Rs 285.92 crore in the year ended March 2026 as against Rs 273.63 crore during the previous year ended March 2025. Sales rose 2.72% to Rs 2126.33 crore in the year ended March 2026 as against Rs 2070.11 crore during the previous year ended March 2025.

Powered by Capital Market - Live News

FDC will hold a meeting of the Board of Directors of the Company on 27 May 2026.

FDC has granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Cefixime for Oral Suspension USP, 100 mg / 5 mL and 200 mg/ 5 mL.